OPAC produces and sells patented and marked CE laboratory reagents, to reduce time (-97%) and costs (-50%) of genetic tests used in cancer diagnosis. Born in 2017, currently OACP distributes its products in 15 countries around the world. The aim of OACP is to become the new standard in cancer diagnosis. To reach its goal, OACP is looking for investments to support its growth and to improve the life of patients around the world.
